ILE VII - Psoriasis
clinical features of ___ = erythematous, scaly, sharply demarcated
plaques in different sizes and shapes
psoriasis
psoriasis is ___ mediated skin disease that causes excessive growth of
skin cells and accumulation of psoriatic lesions
t-cell
moa of ___ = reduction of scale and thickness; inhibition of mitoses and
lymphokines and
through depletion of Langerhans cells
TCS
___ application of TCS without occlusions
daytime
___ application of TCS with occlusions
nighttime
for TCS, do not exceed ___ g daily of topical application to avoid adrenal
suppression
2
high, medium, or low potency TCS: betamethasone dipropionate .05%
high
high, medium, or low potency TCS: clobetasol propionate .05%
high
, high, medium, or low potency TCS: betamethasone valerate
medium
high, medium, or low potency TCS: desoximetasone .05%
medium
fluocinolone acetonide .025%
medium
high, medium, or low potency TCS: fluocinolone .01%
low
high, medium, or low potency TCS: hydrocortisone
low
systemic calcineurin inhibitor for psoriasis
cyclosporine
topical vitamin D analog indicated for plaque psoriasis and psoriasis of
scalp
calcipotriene
moa of ___ = binding to vitamin D receptor; regulation of the normal
growth and production of keratinocytes
calcipotriene
topical retinoid for tx of psoriasis
tazarotene
clinical features of ___ = erythematous, scaly, sharply demarcated
plaques in different sizes and shapes
psoriasis
psoriasis is ___ mediated skin disease that causes excessive growth of
skin cells and accumulation of psoriatic lesions
t-cell
moa of ___ = reduction of scale and thickness; inhibition of mitoses and
lymphokines and
through depletion of Langerhans cells
TCS
___ application of TCS without occlusions
daytime
___ application of TCS with occlusions
nighttime
for TCS, do not exceed ___ g daily of topical application to avoid adrenal
suppression
2
high, medium, or low potency TCS: betamethasone dipropionate .05%
high
high, medium, or low potency TCS: clobetasol propionate .05%
high
, high, medium, or low potency TCS: betamethasone valerate
medium
high, medium, or low potency TCS: desoximetasone .05%
medium
fluocinolone acetonide .025%
medium
high, medium, or low potency TCS: fluocinolone .01%
low
high, medium, or low potency TCS: hydrocortisone
low
systemic calcineurin inhibitor for psoriasis
cyclosporine
topical vitamin D analog indicated for plaque psoriasis and psoriasis of
scalp
calcipotriene
moa of ___ = binding to vitamin D receptor; regulation of the normal
growth and production of keratinocytes
calcipotriene
topical retinoid for tx of psoriasis
tazarotene
